Endocrine Abstracts

ObjectiveThe exact risk of type 2 diabetes in women with polycystic ovary syndrome (PCOS) is unknown. It is also unclear if obesity independently increases the risk in this population. The aim of this study was to systematically review and synthesize the best available evidence regarding the association between PCOS and type 2 diabetes, stratified according to obesity status.MethodsA comprehensive search was ...

Single nucleotide polymorphisms in the glucocorticoid receptor (GR) gene influence tissue sensitivity of GR. Several studies have shown different effects of BclI GR polymorphism on body composition and metabolic parameters. The objective of this study was to explore the effect of BclI GR polymorphism on the body composition and glucose metabolism. Biochemical tests and hormonal evaluation were performed in 106 consecutive women with adrenal incidentalomas (AI...

Introduction: Chronic endogenous hypercortisolism in Cushing’s syndrome imposes a great clinical burden of comorbidities, some of which might persist even after disease remission. Our aim was to analyze factors that predict long-term comorbidities after surgical remission of Cushing’s disease (CD).Subjects and methods: We retrospectively analyzed 37 patents (91.9% females) aged 39.5±13.9 years (10-70) with diagnosed CD, treated in our inst...

Introduction: The diagnostic criteria of polycystic ovary syndrome (PCOS) are still under discussion and the hormonal parameters, including anti-Mullerian hormone range and hyperandrogenism, are not determined. Serum AMH level has been proposed as a surrogate marker for PCOM and could, therefore, be integrated in the diagnostic classifications for PCOS\. The aim of the present study was to characterize hormonal features of PCOS and to establish the most important hormonal para...

Introduction: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. PCOS cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, and is closely linked to metabolic disorders such as obesity and insulin resistance (IR). It was observed that single-point insulin sensitivity estimator (SPISE) index is associated with metabolic abnormalities and could predict glucose regulation ...

Introduction: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. Using ESHRE/ASRM diagnosis of PCOS is considered when 2 of 3 criteria are present: polycystic ovary morphology (PCOM), oligo/anovulation (ANOV) and hyperandrogenism (HA). These criteria form four different phenotypes: A (ANOV, HA, PCOM), B (ANOV, HA), C (HA, PCOM) and D (ANOV, PCOM). Several studies have found differences in anthropometric, hormonal and meta...

Heterozygotes carrying CYP21A2 gene mutations are found in 5-10% of the general population in Mediterranean countries. Accumulating data suggest a survival advantage of this population, despite the fact that carriers of two mutations suffer from either classical or non-classical congenital adrenal hyperplasia (NC-CAH), an entity with increased mortality. In an attempt to elaborate on this issue we evaluated females of reproductive age with CYP21A2 heterozygocity (HET). We have...

Introduction: Polycystic ovarian syndrome (PCOS) is characterized by hyperandrogenism, chronic oligo-/anovulation and polycystic ovarian morphology. Hyperandrogenism is a key diagnostic feature of PCOS and according to ESHRE/ASRM criteria it can be clinical and/or biochemical. SPISE index (single-point insulin sensitivity estimator index) is a new indicator of insulin sensitivity and a predictor of abnormal glucose metabolism. The aim of the research was to analyse association...

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...